Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2015 3
2018 3
2019 1
2020 1
2021 2
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C. Caimi PF, et al. Lancet Oncol. 2021 Jun;22(6):790-800. doi: 10.1016/S1470-2045(21)00139-X. Epub 2021 May 11. Lancet Oncol. 2021. PMID: 33989558 Clinical Trial.
Loncastuximab tesirine is a CD19-directed antibody-drug conjugate with encouraging phase 1 single-agent antitumour activity and acceptable safety in non-Hodgkin lymphoma. ...FUNDING: ADC Therapeutics....
Loncastuximab tesirine is a CD19-directed antibody-drug conjugate with encouraging phase 1 single-agent antitumour activity and accep …
Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma.
Pirosa MC, Stathis A, Zucca E. Pirosa MC, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2309701. doi: 10.1080/21645515.2024.2309701. Epub 2024 Feb 1. Hum Vaccin Immunother. 2024. PMID: 38299612 Free PMC article.
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) require additional treatments, especially those not eligible or not responding to high dose cytotoxic chemotherapy and stem cell transplantation. Over the last few years, several new …
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) require additional treatments, especially tho …
The new therapeutical scenario of Hodgkin lymphoma.
Stathis A, Younes A. Stathis A, et al. Ann Oncol. 2015 Oct;26(10):2026-33. doi: 10.1093/annonc/mdv256. Epub 2015 Jun 2. Ann Oncol. 2015. PMID: 26037796 Free article. Review.
Accordingly, the current efforts are focusing on incorporating these new agents into standard of care regimens, aiming at further improving cure rates, while reducing treatment-related toxicity. In this review, we will focus on the current status of HL the …
Accordingly, the current efforts are focusing on incorporating these new agents into standard of care regimens, aiming at furt …
New agents for the treatment of lymphoma.
Stathis A, Ghielmini M. Stathis A, et al. Ann Oncol. 2012 Sep;23 Suppl 10:x92-8. doi: 10.1093/annonc/mds310. Ann Oncol. 2012. PMID: 22988000 Free article.
Despite improvements in the diagnosis and management of lymphomas, many patients remain incurable with available treatments. advances in preclinical research and a better understanding of the molecular biology of lymphomas have allowed the development of a hi …
Despite improvements in the diagnosis and management of lymphomas, many patients remain incurable with available treatments. a …
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.
Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C. Caimi PF, et al. Haematologica. 2024 Apr 1;109(4):1184-1193. doi: 10.3324/haematol.2023.283459. Haematologica. 2024. PMID: 37646659 Free PMC article. Clinical Trial.
Therapies that demonstrate durable, long-term responses with manageable safety and tolerability are needed for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]), an anti-CD19 antibody c …
Therapies that demonstrate durable, long-term responses with manageable safety and tolerability are needed for patients with relapsed/refrac …
Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review.
Iacoboni G, Zucca E, Ghielmini M, Stathis A. Iacoboni G, et al. Ann Oncol. 2018 May 1;29(5):1120-1129. doi: 10.1093/annonc/mdy113. Ann Oncol. 2018. PMID: 29659676 Free article.
PATIENTS AND METHODS: Reports of phase III trials evaluating the addition of molecularly targeted agents or new monoclonal antibodies to the classic R-CHOP backbone in first-line induction or maintenance treatment were reviewed. ...Phase I/II trials failed to …
PATIENTS AND METHODS: Reports of phase III trials evaluating the addition of molecularly targeted agents or new monoclonal ant …
PI3Kdelta activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
Arribas AJ, Gaudio E, Napoli S, Yvon Herbaux CJ, Tarantelli C, Bordone RP, Cascione L, Munz N, Aresu L, Sgrignani J, Rinaldi A, Kwee I, Rossi D, Cavalli A, Zucca E, Stussi G, Stathis A, Sloss C, Davids MS, Bertoni F. Arribas AJ, et al. bioRxiv [Preprint]. 2023 Nov 16:2023.11.14.566994. doi: 10.1101/2023.11.14.566994. bioRxiv. 2023. PMID: 38014209 Free PMC article. Preprint.
Despite notable progress in recent decades, we still face challenges in achieving a cure for a substantial number of lymphoma patients (1,2). A pertinent example is diffuse large B cell lymphoma (DLBCL), the most prevalent type of lymphoma (3). ...Based on th …
Despite notable progress in recent decades, we still face challenges in achieving a cure for a substantial number of lymphoma patient …
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
Sartori G, Tarantelli C, Spriano F, Gaudio E, Cascione L, Mascia M, Barreca M, Arribas AJ, Licenziato L, Golino G, Ferragamo A, Pileri S, Damia G, Zucca E, Stathis A, Politz O, Wengner AM, Bertoni F. Sartori G, et al. Br J Haematol. 2024 Jan;204(1):191-205. doi: 10.1111/bjh.19218. Epub 2023 Nov 27. Br J Haematol. 2024. PMID: 38011941
ATR inhibitors are agents that have shown considerable clinical potential in this context. ...This activity is present in both DDR-proficient and DDR-deficient lymphoma models. Furthermore, a combination of ATR and PI3K inhibition by treatment with elimuserti …
ATR inhibitors are agents that have shown considerable clinical potential in this context. ...This activity is present in both DDR-pr …
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents.
Spriano F, Chung EYL, Gaudio E, Tarantelli C, Cascione L, Napoli S, Jessen K, Carrassa L, Priebe V, Sartori G, Graham G, Selvanathan SP, Cavalli A, Rinaldi A, Kwee I, Testoni M, Genini D, Ye BH, Zucca E, Stathis A, Lannutti B, Toretsky JA, Bertoni F. Spriano F, et al. Clin Cancer Res. 2019 Aug 15;25(16):5167-5176. doi: 10.1158/1078-0432.CCR-18-2718. Epub 2019 Jun 10. Clin Cancer Res. 2019. PMID: 31182435
YK-4-279 and TK-216 interfere with protein interactions of ETS family members SPIB, in activated B-cell-like type diffuse large B-cell lymphomas, and SPI1, in germinal center B-cell-type diffuse large B-cell lymphomas. CONCLUSIONS: The ETS inhibitor YK-4-279 and its …
YK-4-279 and TK-216 interfere with protein interactions of ETS family members SPIB, in activated B-cell-like type diffuse large B-cell ly …
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma.
Collins GP, Eyre TA, Schmitz-Rohmer D, Townsend W, Popat R, Giulino-Roth L, Fields PA, Krasniqi F, Soussain C, Stathis A, Andjelkovic N, Cunningham D, Mandic D, Radulovic S, Tijanic I, Horowitz NA, Kurtovic S, Schorb E, Schmidt C, Dimitrijević S, Dreyling M. Collins GP, et al. Hemasphere. 2021 Oct 27;5(11):e656. doi: 10.1097/HS9.0000000000000656. eCollection 2021 Nov. Hemasphere. 2021. PMID: 34901759 Free PMC article.
Fifty patients were enrolled and started treatment. The most common histologies were diffuse large B-cell lymphoma (n = 17), follicular lymphoma (n = 9), T-cell lymphoma (n = 8), and others (mostly indolent). Patients had been treated with a median of …
Fifty patients were enrolled and started treatment. The most common histologies were diffuse large B-cell lymphoma (n = 17), f …
16 results